Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

Consensus was predefined as agreement of 75% or higher.

Panellists agreed that patient preferences are central to decision making (100%) and that a second breast-conserving therapy represents a reasonable option for selected patients (100%).

Criteria associated with greater suitability for second breast-conserving therapy included an interval between surgeries of at least 60 months, low-risk accelerated partial breast irradiation classification, luminal molecular profile, and no grade 3 late toxicity related to the first breast-conserving therapy.